<section class="ba-be-container py-5">
  <section class="container">
    <section class="section-header text-center mb-5">
      <h2 class="sv_primary fw-bold">Bioavailability / Bioequivalence Services</h2>
      <p class="sv_secondary fs-5">
        Delivering audit-ready, protocol-driven oversight for global regulatory success
      </p>
    </section>

    <section class="row g-5">
      <!-- Bioequivalence Column -->
      <section class="col-lg-6">
        <section class="info-card h-100 shadow-sm p-4 rounded-4 border">
          <h3 class="fw-bold sv_primary mb-3">Bioequivalence Study Monitoring Services</h3>
          <p><strong>Enabling Regulatory Confidence Through Precision Oversight</strong></p>
          <p>
            We deliver BE study monitoring aligned with global regulations (ICH-GCP, FDA, EMA, WHO, CDSCO) enabling inspection-ready data across geographies.
          </p>
          <ul>
            <li><strong>Protocol Compliance Monitoring:</strong> SOP, 21 CFR, EU CTR 536/2014 alignment and real-time deviation management.</li>
            <li><strong>Clinical Phase Oversight:</strong> Monitors trained in dosing, PK fidelity, informed consent & crossover designs.</li>
            <li><strong>Risk-Based Site Monitoring:</strong> Facility, equipment, and cold chain inspections per FDA/EMA mandates.</li>
            <li><strong>SDV & eCRF Validation:</strong> TransCelerate RBM methodology for GxP compliance.</li>
            <li><strong>AE & Deviation Management:</strong> ICH E2A, MedDRA coded, CAPA-driven event tracking.</li>
            <li><strong>Monitoring Deliverables:</strong> eCTD-ready reports, logs, and query resolution summaries.</li>
          </ul>
          <p class="mt-3"><strong>Why Sponsors Choose SafeVig:</strong></p>
          <ul>
            <li>GCP-certified early-phase clinical monitors</li>
            <li>Supports BE/BA, 505(b)(2), global bridging studies</li>
            <li>Lifecycle support from site to CSR</li>
            <li>Proven compliance with USFDA, ANSM, CDSCO</li>
          </ul>
        </section>
      </section>

      <!-- Bioavailability Column -->
      <section class="col-lg-6">
        <section class="info-card h-100 shadow-sm p-4 rounded-4 border">
          <h3 class="fw-bold sv_primary mb-3">Bioavailability Study Monitoring Services</h3>
          <p><strong>Advancing Regulatory Success Through Precision and Scientific Integrity</strong></p>
          <p>
            We offer BA study monitoring aligned with ICH-GCP, FDA, EMA, CDSCO, TGA, and Health Canada to enable reproducible, regulatory-accepted data.
          </p>
          <ul>
            <li><strong>Compliance Oversight:</strong> Aligned with ICH E6(R2), 21 CFR Parts 50 & 56, EU 2001/20/EC. Ensures criteria adherence and informed consent documentation.</li>
            <li><strong>PK Sampling Oversight:</strong> Predefined logs, matrix-specific timing, real-time supervision.</li>
            <li><strong>Sample Chain of Custody:</strong> GLP, audit trails, validated bioanalytical logistics.</li>
            <li><strong>Source Document Review:</strong> 100% SDV + RBM hybrid verification with traceability.</li>
            <li><strong>AE Management:</strong> Integrated CAPA, ICH E2A, real-time escalation framework.</li>
            <li><strong>Monitoring Output:</strong> Visit reports, site metrics, reconciled data logs, eCTD-ready.</li>
          </ul>
          <p class="mt-3"><strong>Why SafeVig for BA:</strong></p>
          <ul>
            <li>Expert PK monitors for SD/MD, fed/fasted, special populations</li>
            <li>eTMF, eCRF, RBM dashboards for efficient oversight</li>
            <li>Centers in LATAM, Southeast Asia, India, EU</li>
            <li>Supports small molecules, MR, 505(b)(2), nutraceuticals</li>
          </ul>
        </section>
      </section>
    </section>
  </section>
</section>







